fashion -WSS

fashion

author：explore 2025-09-27 22:56:38 - browse：95

Hospital power in DC — Mike Reddy for STAT

WASHINGTON — Democrats unilaterally drove major reforms to the health insurance and the pharmaceutical industries without a single Republican vote in recent years. But hospitals may be a health care giant they’re unable to confront alone.

Unlike Republicans, Democrats have seized on lowering health care costs as a politically winning issue in one election cycle after another. They have campaigned on passing health insurance reform, and then protecting it. And after 20 years, they finally delivered on a promise to empower the federal government to lower drug prices in 2022.

But the remaining elephant in the room is hospital costs, which make up the biggest share of U.S. health care spending. And Democratic leaders in Congress have shown this year that they are unable to agree on even the most incremental steps toward addressing the cost of hospital care.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： UnitedHealth’s Optum accused of antitrust violations in California

explore

knowledge

WSS

Stem cell treatment guidelines are released by FDA

Amazon on where the company's health care bets are headed next

The 10 drugs up first for Medicare price negotiation

How to pay for weight loss drugs and save Medicare

Will the market for weight loss drugs really reach $100 billion?

How generative AI is inspiring dreams of a health data revolution

leisure time

fashion

knowledge

Wildfire smoke exposes gaps in outdoor worker protections

FDA investigates CAR

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

The 10 drugs up first for Medicare price negotiation

Drug repurposing or repositioning? The language matters

As biotech industry slumps, bioscience job market is upside down

New air purifier tech could be key to improving indoor air quality

What to do when lifesaving products contribute to climate change

23andMe had bad news about my health. I wish a person had delivered it

Illumina names Agilent executive as new CEO

focus

BIO selects John Crowley as new CEO

How to fix cancer clinical trials' diversity problem

House transparency, PBM reform bill gains bipartisan support

AstraZeneca chief proposes a novel edit to the drug pricing bill

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

How to protect patients from sexual assault

explore

explore

knowledge

hotspot